ImmunityBio

Company snapshot

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Execut

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ImmunityBio. Not investment advice.

• approval Jun 2, 2026

  ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles

• Presentation Jun 25, 2026
  Business update and 2026 financial results with pipeline progress
• Congress Jun 22, 2026
  BIO
• Congress May 17, 2026
  ISPOR 2026

Recent activity

Latest pipeline, patent, and corporate events for ImmunityBio.

1. Jun 8, 2026 Clinical update

   QUILT-2.005 — Phase 2

2. Jun 8, 2026 Clinical update

   BCG (50mg/instillation) + N-803 (400 μg/instillation) — Phase 2

View all clinical trial activity →

• What is ImmunityBio?

  Immunitybio Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity f

• Is ImmunityBio publicly traded?

  ImmunityBio appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ImmunityBio develop or market?

  We link 5 drug profile(s) where ImmunityBio is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/immunitybio-ireland-limited#company-drugs.

• What are the latest developments for ImmunityBio?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ImmunityBio focus on?

  ImmunityBio focuses on Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer based on our analysis of their pipeline programs and drug development activities.